Lake Street lifts Cellebrite shares target By

On Friday, Lake Street Capital Markets adjusted its price target for shares of Cellebrite (NASDAQ:CLBT), raising it to $13.50 from the previous target of $13.00, while reiterating a Buy rating on the stock. The firm’s decision follows Cellebrite’s first-quarter performance, which exceeded expectations, and a second-quarter guide that was slightly above consensus.

The company, known for its digital intelligence solutions, has chosen to maintain its outlook for the year 2024 despite the positive indicators. Lake Street Capital Markets commented on this decision, noting that should Cellebrite continue to execute effectively in the second quarter and benefit from a supportive macroeconomic environment, there is potential for the company to revise its 2024 outlook upwards during the second-quarter earnings announcement in August.

In response to these developments, Lake Street Capital Markets has increased its forecast for Cellebrite’s performance in 2024. The firm’s analysts attribute the higher price target to the company’s solid execution and the positive momentum that Cellebrite is currently experiencing.

Cellebrite’s adherence to its 2024 guidance, despite the better-than-expected results and forecasts, suggests a cautious approach amid a dynamic market environment.

InvestingPro Insights

As Cellebrite (NASDAQ:CLBT) garners attention following the updated price target from Lake Street Capital Markets, several metrics and tips from InvestingPro provide a deeper understanding of the company’s financial health and market performance. The company’s impressive gross profit margin, which stood at 87.33% for the last twelve months as of Q4 2023, indicates a strong ability to control costs relative to revenue. This aligns with the firm’s ability to exceed expectations in the first quarter and could be a factor in the potential upward revision of its 2024 outlook.

InvestingPro Tips highlight that Cellebrite holds more cash than debt on its balance sheet, and analysts have revised their earnings upwards for the upcoming period, signaling confidence in the company’s financial stability and future performance. Additionally, the company’s stock has seen a significant return over the last year, with a 108.42% price total return, reflecting investor optimism and market traction.

InvestingPro Data further reveals a strong revenue growth of 24.98% for the last twelve months as of Q4 2023, with a substantial quarterly increase of 68.16% in Q4 2023. While Cellebrite’s P/E Ratio is not applicable due to negative earnings, the PEG Ratio of 0.17 suggests potential for future earnings growth at a rate that could justify the current stock price. Lastly, the company’s market cap stands at $2.44 billion USD, underscoring its significant presence in the digital intelligence solutions market.

For those looking to delve deeper into Cellebrite’s financials and market potential, InvestingPro offers additional insights and tips. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. With 13 additional InvestingPro Tips available, investors can gain a comprehensive view of the company’s prospects and make informed decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.


This website uses cookies. By continuing to use this site, you accept our use of cookies.